MedTrace Logo

Neurology Measures in FA Children

NCT03418740 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2025-01-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to identify ways to follow progression of Friedreich's Ataxia (FA) and be able to measure changes over time in children with FA. Participants will have biannual visits to observe how the disease progresses over time and determine the rate of progression.

Funding Source- Food and Drug Administration Office of Orphan Products Development (FDA OOPD).

Conditions

  • Friedreich Ataxia

Sponsors & Collaborators

Principal Investigators

  • David Lynch, MD, PhD · Children's Hospital of Philadelphia

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-20
Primary Completion
2023-02-02
Completion
2023-02-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03418740 on ClinicalTrials.gov